Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarker... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'Evaluating the efficacy and safety of Platelet Rich Plasma for patients with Peyronie’s disease: ... Read More
U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07817199) titled 'Time Comparison of Interventions on Bowel Programs in Spinal Cord Injury' on Sept. 01. Br... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'SURFactant Administration by SUPraglottic Airway (the SURFSUP Trial)'. The following are the othe... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpa... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemothe... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy,and Pharmacokinetics o... Read More
U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818707) titled 'Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surge... Read More
Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Part... Read More